HHS Secretary Alex Azar, once a pharmaceutical company executive, believes his former colleagues can easily make up the loss President Trump's new drug pricing proposal would create. If not, they may need to make personnel changes, he suggested.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?